Cilofexor-tromethamine-GS-9674-tromethamine-生命科學(xué)試劑-MCE

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemECilofexortromethamineCat.No.:HY-109083ACASNo.:2253764-93-9Synonyms:GS-9674tromethamine分?式:C??H??Cl?N?O?分?量:707.99作?靶點(diǎn):Autophagy;FXR作?通路:Autophagy;MetabolicEnzyme/Protease儲(chǔ)存?式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY?物活性Cilofexortromethamine(GS-9674tromethamine)?種?類(lèi)醇法尼烯氧化物受體激動(dòng)劑，具有改膽汁淤積和肝損傷標(biāo)志物的活性。Cilofexortromethamine在?肝硬化的患者中顯?了良好的耐受性，并導(dǎo)致肝?化指標(biāo)和膽汁淤積標(biāo)志物的顯著改。Cilofexortromethamine為處理原發(fā)性硬化性膽管炎提供了潛在的抑制選擇。戶(hù)使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?Science.2023Jun9;380(6649):eabo2296.?NatCommun.2024May13;15(1):4034.?JHEPRep.2023Sep25,100917.?BiomedPharmacother.2024Feb29:173:116331.?ArchToxicol.2022Mar10.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].TraunerM,etal.TheNonsteroidalFarnesoidXReceptorAgonistCilofexor(GS-9674)ImprovesMarkersofCholestasisandLiverInjuryinPatientsWithPrimarySclerosingCholangitis.Hepatology.2019Sep;70(3):788-801.[2].PatelK,etal.Cilofexor,aNonsteroidalFXRAgonist,inNon-CirrhoticPatientswithNonalcoholicSteatohepatitis:APhase2RandomizedControlledTrial.Hepatology.2020Mar1.1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE[3].P.Schwab,etal.TheFXRagonistGS-9674reducesfibrosisandportalhypertensioninaratmodelofNASH.April2018,Volume68,Supplement1,PagesS471-S472.[4].TheNonsteroidalFarnesoidXReceptorAgonistCilofexor(GS-9674)ImprovesMarkersofCholestasisandLiverInjuryinPatientsWithPrimarySclerosingCholangitisMcePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792;021-58